Condition
Immunomodulatory Drugs
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Zn Se Myrin P Fort
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Zn Se Myrin P Fort1
- Killercell Immunoglobulinlike Receptors Kirs Testing1
- Myrin P Fort1
- Zn Se Supplemented Cookies1
Active Sponsors
- Calla IVF Center1
- University of Lahore1
Related Conditions
- Kir Alleles Kir Aa1
- Tuberculosis1
- Killercell Immunoglobulinlike Receptors Kirs1